MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Juniper Pharmaceuticals Company Profile (NASDAQ:JNP)

Consensus Ratings for Juniper Pharmaceuticals (NASDAQ:JNP) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.33 (138.10% upside)

Analysts' Ratings History for Juniper Pharmaceuticals (NASDAQ:JNP)
Show:
DateFirmActionRatingPrice TargetActions
5/24/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Northland SecuritiesInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Roth CapitalBoost Price TargetBuy$15.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Juniper Pharmaceuticals (NASDAQ:JNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q116($0.08)$0.03$9.13 million$12.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.02)($0.19)$7.89 million$7.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.05)$0.09$7.10 million$11.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.02)($0.03)$8.35 million$10.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115$0.04$0.07$7.80 million$8.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414$0.07($0.05)$7.93 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314$0.12$0.34$9.74 million$11.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q2$0.11$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114$0.07$0.01$6.30 million$7.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413$0.08$7.10 million$7.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313$0.16$0.20$6.75 million$7.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013$0.02$0.03$6.50 million$7.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013$0.03$0.01$6.50 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q4 2012$0.02$0.03$7.60 million$6.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Juniper Pharmaceuticals (NASDAQ:JNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.11$0.11$0.11
Q2 20161$0.10$0.10$0.10
Q3 20161$0.12$0.12$0.12
Q4 20161$0.08$0.08$0.08
(Data provided by Zacks Investment Research)
Dividend History for Juniper Pharmaceuticals (NASDAQ:JNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Juniper Pharmaceuticals (NASDAQ:JNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/4/2015C Ann MerrifieldDirectorBuy1,600$12.14$19,424.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Nikin PatelCOOBuy5,000$11.82$59,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Frank Condella JrCEOBuy5,000$11.68$58,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015C Ann MerrifieldDirectorBuy3,000$9.90$29,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Frank M ArmstrongDirectorBuy1,255$7.95$9,977.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Nikin PatelCOOBuy13,500$7.52$101,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Frank Condella JrCEOBuy10,000$7.36$73,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Donald H HunterDirectorBuy1,000$5.98$5,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Frank Condella JrCEOBuy10,000$5.98$59,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Frank Condella JrCEOBuy10,000$6.65$66,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Juniper Pharmaceuticals (NASDAQ:JNP)
DateHeadline
06/17/16 07:32 AMJuniper Pharma (JNP) Announces Publication of Data from Two COL-1077 Phase 1s; Plans to Report Topline Data in Q3
06/16/16 04:53 PMJuniper Pharmaceuticals Announces Phase 1 Studies of COL-1077 Lidocaine Vaginal Gel Published in Peer Reviewed Scientific Journal
06/15/16 04:18 PMJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements a -
06/14/16 07:25 AMCatalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 6.6% -
06/03/16 07:30 AMAchaogen (AKAO) Shows Strength: Stock Moves 13% Higher - Achaogen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. A better-ranked med-drugs stock is Juniper Pharmaceuticals, Inc. (JNP - Snapshot Report) , sporting a Zacks Rank #1 (Strong Buy). Is AKAO going up? Or down? Predict to see what ...
06/02/16 07:36 AMJuniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella - BOSTON, June 2, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that Frank C. Condella, Jr., plans to retire as the Company's President and Chief ...
06/02/16 06:06 AMJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, -
06/01/16 04:05 PMARIAD (ARIA) Commences Phase I/II Study on Cancer Drug -
05/29/16 11:30 AMPerformance at a Glance on Juniper Pharmaceuticals, Inc. (:JNP) - HNN - Performance at a Glance on Juniper Pharmaceuticals, Inc. (:JNP)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Juniper Pharmaceuticals, Inc. (:JNP)'s stock has performed at various points in its past. Currently ...and more »
05/26/16 10:53 AMJuniper Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference - PR Newswire (press release) - Juniper Pharmaceuticals to Present at Jefferies 2016 Healthcare ConferencePR Newswire (press release)BOSTON, May 24, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Frank Condella, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on ...and more »
05/24/16 09:15 AMJuniper Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference - [PR Newswire] - BOSTON, May 24, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Frank Condella, Chief Executive Officer, will present ...
05/18/16 12:42 PMJuniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/04/16 06:07 AMQ1 2016 Juniper Pharmaceuticals Inc Earnings Release - Time Not Supplied -
05/04/16 05:21 AMJuniper Pharmaceuticals posts 1Q profit -
05/04/16 05:00 AMJuniper Pharmaceuticals Reports First Quarter 2016 Financial Results - [PR Newswire] - BOSTON, May 4, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results ...
04/26/16 07:00 AMJuniper Pharmaceuticals to Report First Quarter 2016 Results on May 4, 2016 - [PR Newswire] - BOSTON, April 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold ...
03/30/16 07:00 AMJuniper Pharmaceuticals Appoints Dr. Herman Weiss as Vice President, Medical Affairs and Clinical Development - [PR Newswire] - BOSTON, March 30, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has appointed ...
03/28/16 10:30 AMJuniper's board has greater ratio of women than any other firm in Mass. -
03/11/16 02:02 PMJuniper Pharmaceuticals Inc (NASDAQ:JNP) 4Q Loss Widens - Market Exclusive - Market ExclusiveJuniper Pharmaceuticals Inc (NASDAQ:JNP) 4Q Loss WidensMarket ExclusiveJuniper Pharmaceuticals Inc (NASDAQ:JNP) reported its financial results for the fourth quarter that showed a wider net loss and missed Wall Street analysts' estimations. The company's top line rose marginally but also fell shy of analyst expectations ...Juniper Pharmaceuticals Widens Q4 Loss on Slightly Stronger Revenues (NASDAQ:JNP)Sonoran Weekly ReviewJuniper Pharmaceuticals' (JNP) CEO Frank Condella on Q4 2015 Results - Earnings Call TranscriptSeeking AlphaJuniper Pharma (JNP) Posts Q4 Loss of $0.19/Share as Revenue Rise to $7.6MStreetInsider.comall 8 news articles »
03/11/16 02:02 PMJuniper Pharmaceuticals Inc (NASDAQ:JNP) 4Q Loss Widens - Juniper Pharmaceuticals Inc (NASDAQ:JNP) reported its financial results for the fourth quarter that showed a wider net loss and missed Wall Street analysts’ estimations. The company’s top line rose marginally but also fell shy of analyst expectations.
03/10/16 09:00 AMJuniper Pharmaceuticals posts 4Q loss -
03/10/16 06:07 AMQ4 2015 Juniper Pharmaceuticals Inc Earnings Release - Time Not Supplied -
03/10/16 05:26 AMJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
03/10/16 05:22 AM6:22 am Juniper Pharma reports Q4 results -
03/10/16 05:17 AMJuniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results - [PR Newswire] - BOSTON, March 10, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results ...
03/05/16 01:28 PMHealthcare ratings roundup - new coverage #1 - Seeking Alpha - Healthcare ratings roundup - new coverage #1Seeking AlphaRegeneron Pharmaceuticals (NASDAQ:REGN) initiated with Neutral rating and $450 (12% upside) price target by SunTrust Robinson Humphrey. GW Pharmaceuticals (NASDAQ:GWPH) initiated with Sell rating and implied price target of $30 (22% downside ...
03/01/16 06:09 AMCoverage initiated on Juniper Pharma by H.C. Wainwright -
02/29/16 01:51 PMJuniper Pharmaceuticals to Present at ROTH Conference on March 14, 2016 - PR Newswire (press release) - Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2016PR Newswire (press release)BOSTON, Feb. 29, 2016 /PRNewswire/ -- George Elston, Chief Financial Officer of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will present at the 28th Annual ROTH Conference in Dana Point, CA on Monday, March 14, 2016 at ...and more »
02/29/16 07:05 AMJuniper Pharmaceuticals to Present at ROTH Conference on March 14, 2016 - [PR Newswire] - BOSTON, Feb. 29, 2016 /PRNewswire/ -- George Elston, Chief Financial Officer of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will present at the 28th Annual ...
02/25/16 01:37 PMJuniper Pharmaceuticals to Report Fourth Quarter and Year End 2015 Results on March 10, 2016 - PR Newswire (press release) - Juniper Pharmaceuticals to Report Fourth Quarter and Year End 2015 Results on March 10, 2016PR Newswire (press release)BOSTON, Feb. 25, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 10, 2016, to discuss financial results ...and more »
02/25/16 07:00 AMJuniper Pharmaceuticals to Report Fourth Quarter and Year End 2015 Results on March 10, 2016 - [PR Newswire] - BOSTON, Feb. 25, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold ...
02/24/16 01:38 PMJuniper Pharmaceuticals, Inc. (JNP) - Juniper Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system ...
02/15/16 01:05 PMJUNIPER AND CRYSTEC SIGN AGREEMENT FOR NEXT GENERATION MEDICINES - Bio-IT World - JUNIPER AND CRYSTEC SIGN AGREEMENT FOR NEXT GENERATION MEDICINESBio-IT WorldNOTTINGHAM, UK - Feb 15, 2016 - Nottingham, UK - Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), will work with CrystecPharma on a major multi-partner project as part of the Advanced Manufacturing Supply Chain ...
02/01/16 12:52 PMJUNIPER PHARMA SERVICES TO REFORMULATE PHARMAUST CANDIDATE FOR PHASE II TRIALS - Bio-IT World - JUNIPER PHARMA SERVICES TO REFORMULATE PHARMAUST CANDIDATE FOR PHASE II TRIALSBio-IT WorldNOTTINGHAM, UNITED KINGDOM - Feb 1, 2016 - Nottingham, UK - Juniper Pharma Services (“the company”), a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), has been selected by PharmAust Limited (“PharmAust”) (ASX: PAA) to reformulate ...
01/21/16 12:48 PMProminent Physicians Join Juniper Pharmaceuticals' Scientific Advisory Board - PR Newswire (press release) - Prominent Physicians Join Juniper Pharmaceuticals' Scientific Advisory BoardPR Newswire (press release)BOSTON, Jan. 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") announced today the addition of two new Scientific Advisory Board (SAB) members: Linda Giudice, MD, PhD, and Marianne Mann, MD.and more »
01/20/16 03:20 PMJuniper Pharmaceuticals, Inc.: Strong price momentum but will it sustain? -
01/20/16 07:00 AMProminent Physicians Join Juniper Pharmaceuticals' Scientific Advisory Board - [PR Newswire] - BOSTON, Jan. 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") announced today the addition of two new Scientific Advisory Board (SAB) ...
01/16/16 11:56 AMMarket Movers: Juniper Pharmaceuticals, Inc. (NASDAQ:JNP), Oi SA (ADR) (NYSE ... - Stock Transcript - Market Movers: Juniper Pharmaceuticals, Inc. (NASDAQ:JNP), Oi SA (ADR) (NYSE ...Stock TranscriptJuniper Pharmaceuticals, Inc. (NASDAQ:JNP) announced the expansion of its lead clinical trial, and the submission of a pre-IND meeting request with the FDA for its oxybutynin intra-vaginal ring (IVR) for treatment of overactive bladder. The Company ...and more »
01/14/16 07:05 AMJuniper Pharmaceuticals (JNP) in Focus: Stock Jumps 7.8% -
01/11/16 05:50 AMJuniper Pharmaceuticals Expands Lead Phase 2b Trial, Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product, and Adds Four Key Executives - [PR Newswire] - BOSTON, Jan. 11, 2016 /PRNewswire/ -- Building on its recently disclosed refocus on internal product development, Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or "the Company"), today announced the expansion of its lead clinical trial, and the submission of a pre-IND meeting request with the FDA for its oxybutynin intra-vaginal ring (IVR) for treatment of overactive bladder. The Company also announced the hiring of four new executives to support its future growth. "Juniper's key product candidates have progressed considerably over the past few months," said Frank Condella, CEO of Juniper Pharmaceuticals.
12/23/15 12:00 PMJuniper Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/08/15 12:17 PMJUNIPER PHARMACEUTICALS INC Financials -
12/03/15 07:46 AMWhy Juniper Pharmaceuticals (JNP) Stock Might be a Great Pick -
11/23/15 05:58 AM​How a $150B-plus merger between Pfizer and Allergan would affect Massachusetts -
11/18/15 08:00 AMJuniper Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015 - [PR Newswire] - BOSTON, Nov. 18, 2015 /PRNewswire/ -- Frank Condella, CEO of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or "the Company"), will present at the 27 th Annual Piper Jaffray ...
11/13/15 08:20 AMJuniper Pharmaceuticals Adds Three New Products to its Proprietary Pipeline - [PR Newswire] - BOSTON and NEW YORK, Nov. 13, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced details of its portfolio pipeline, focused on ...
11/12/15 05:33 PMJUNIPER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
11/12/15 01:49 PMThomson ONE Initially Understates Juniper Pharmaceuticals' Third Quarter 2015 Results in First Call - [PR Newswire] - BOSTON, Nov. 12, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced that Thomson ONE initially reported understated Juniper ...
11/12/15 11:04 AMSurModics (SRDX) Q4 Earnings, Revenues Beat Estimates -
11/10/15 03:30 PMJuniper Pharmaceuticals Reports Third Quarter 2015 Financial Results - [PR Newswire] - BOSTON, Nov. 10, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results ...
About Juniper Pharmaceuticals

Juniper Pharmaceuticals logoJuniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women's health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women's health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: JNP
  • CUSIP:
Key Metrics:
  • Previous Close: $6.86
  • 50 Day Moving Average: $7.13
  • 200 Day Moving Average: $7.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $74.10M
  • Current Quarter EPS Consensus Estimate: $-0.11 EPS
Additional Links:
Juniper Pharmaceuticals (NASDAQ:JNP) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha